Abstract:BACKGROUND:Cardiac hypertrophy is a prominent feature of heart remodeling, which may eventually lead to heart failure. Tongmaiyangxin (TMYX) pills are a clinically used botanical drug for treating multiple cardiovascular diseases including chronic heart failure. The aim of the current study was to identify the bioactive compounds in Tongmaiyangxin pills that attenuate cardiomyocytes hypertrophy, and to investigate the underlying mechanism of action. METHODS AND RESULTS:The anti-hypertrophy effect of TMYX was validated in isoproterenol-induced cardiac hypertrophy model in C57BL/6 mice. After TMYX treatment for 2 weeks, the heart ejection fraction and fractional shortening of the mice model was increased by approximately 20% and 15%, respectively, (p < 0.05). Besides, TMYX dose-dependently reduced the cross section area of cardiomyocytes in the angiotensin-II induced hypertrophy H9c2 model (p < 0.01). Combining high content screening and liquid chromatography mass spectrometry, four compounds with anti-cardiac hypertrophy effects were identified from TMYX, which includes emodin, licoisoflavone A, licoricone and glyasperin A. Licoisoflavone A is one of the compounds with most significant protective effect and we continued to investigate the mechanism. Primary cultures of neonatal rat cardiomyocytes were treated with a hypertrophic agonist phenylephrine (PE) in the presence or absence of licoisoflavone A. After 48 h of treatment, cells were harvested and mitochondrial acetylation was analyzed by western blotting and Image analysis. Interestingly, the results suggested that the anti-hypertrophic effects of licoisoflavone A depend on the activation of the deacetylase Sirt3 (p < 0.01). Finally, we showed that licoisoflavone A-treatment was able to decrease relative ANF and BNP levels in the hypertrophic cardiac cells (p < 0.01), but not in cells co-treated with Sirt3 inhibitors (3-TYP) (p > 0.05). CONCLUSION:TMYX exerts its anti-hypertrophy effect possibly through upregulating Sirt3 expression. Four compounds were identified from TMYX which may be responsible for the anti-hypertrophy effect. Among these compounds, licoisoflavone A was demonstrated to block the hypertrophic response of cardiomyocytes, which required its positive regulation on the expression of Sirt3. These results suggested that licoisoflavone A is a potential Sirt3 activator with therapeutic effect on cardiac hypertrophy.

[Role of Liver X Receptors on Cardiomyocyte Hypertrophy].

The Liver X Receptor Ligand Agonist Inhibits Hypertrophy in Murine HL-1 Cardiomyocytes in vitro

[Effect of Liver X Receptor Agonist T0901317 on Endothelin-1 Induced Murine HL-1 Cardiomyocytes Hypertrophy].

High Content Screening Identifies Licoisoflavone A As a Bioactive Compound of Tongmaiyangxin Pills to Restrain Cardiomyocyte Hypertrophy Via Activating Sirt3.

Liver X receptors attenuate anoxia/reoxygenation injury in neonatal rat cardiomyocytes

Activation Of Lxr Alpha Improves Cardiac Remodeling Induced By Pulmonary Artery Hypertension In Rats

Activation of Liver-X-Receptor Α but Not Liver-X-Receptor Β Protects Against Myocardial Ischemia/Reperfusion Injury

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

Abstract 9571: Activation of LXRα but Not LXRβ Protects the Heart from Ischemia/Reperfusion Injury

Activation of LXRα improves cardiac remodeling induced by pulmonary artery hypertension in rats

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

<strong><b></b></strong>Impaired Adipose Tissue Expansion Caused by LXR Activation is Associated with Insulin Resistance in HFD Mice

GW24-e3157 Possible Mechanism of Liver X Receptors Attenuate Ischaemia Reperfusion Injury in Isolated Rat Hearts

LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice

Increased mortality and aggravation of heart failure in liver X receptor-α knockout mice after myocardial infarction

The Effect of T0901317 on ATP-binding Cassette Transporter A1 and Niemann-Pick Type C1 in Apoe-/- Mice.

Liver X Receptors And Their Agonists: Targeting For Cholesterol Homeostasis And Cardiovascular Diseases

Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway.

Oxidized LDL but Not Angiotensin II Induces Cardiomyocyte Hypertrophic Responses Through the Interaction Between LOX-1 and AT1 Receptors

Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling.

Liver X Receptors (lxrs) Regulate Apolipoprotein Aiv-Implications of the Antiatherosclerotic Effect of Lxr Agonists